- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06055920
De PEERLESS II-studie
PEERLESS II: RCT van FlowTriever versus alleen antistolling bij longembolie
This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Aalst, België
- Onze Lieve Vrouwziekenhuis
-
-
-
-
British Columbia
-
New Westminster, British Columbia, Canada, V3L 3W7
- Royal Columbian Hospital
-
Surrey, British Columbia, Canada, V3V 1Z2
- Surrey Memorial Hospital
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Vancouver General Hospital
-
-
-
-
-
Aarhus, Denemarken, 8200
- Aarhus University Hospital
-
-
-
-
-
Augsburg, Duitsland
- University Hospital Augsburg
-
Bad Krozingen, Duitsland
- Universitäts-Herzzentrum Bad Krozingen
-
Berlin, Duitsland
- Charité Campus Virchow Clinic - Klinik fuer Radiologie
-
Berlin, Duitsland
- Unfall Krankenhaus Berlin
-
Cologne, Duitsland
- University Hospital Cologne
-
Dresden, Duitsland
- HerzZentrum Dresden Universitaetsklinik
-
Düsseldorf, Duitsland
- Universitaetsklinikum Dὒsseldorf
-
Essen, Duitsland
- Universitaetsklinikum Essen
-
Essen, Duitsland
- Elisabeth Hospital GmbH
-
Frankfurt, Duitsland
- CCB Frankfurt
-
Hamburg, Duitsland
- Universitaetsklinikum Hamburg Eppendorf
-
Heidelberg, Duitsland
- University Hospital - Heidelberg
-
Kaiserslautern, Duitsland
- Westpfalz Klinikum
-
Munich, Duitsland
- Klinikum rechts der Isar (TUM)
-
Munich, Duitsland
- Ludwig Maximilians-University
-
Regensburg, Duitsland
- University Hospital Regensburg
-
Villingen-Schwenningen, Duitsland
- Schwarzwald-Baar-Klinikum
-
-
-
-
-
Lille, Frankrijk
- CHU Lille
-
Lyon, Frankrijk
- Hôpital Louis Pradel
-
Marseille, Frankrijk
- Hôpital Nord Marseille
-
Marseille, Frankrijk
- AP-HM Hopital La Timone
-
-
-
-
-
Madrid, Spanje
- Hopital Clinico Universitario San Carlos
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35243
- Brookwood Medical Center
-
Birmingham, Alabama, Verenigde Staten, 35205
- UAB Division of Cardiovascular Disease
-
-
California
-
Pasadena, California, Verenigde Staten, 91105
- Huntington Memorial Hospital
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- University of Colorado, Denver
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06520
- Yale University
-
-
Florida
-
Largo, Florida, Verenigde Staten, 33770
- HCA FL Largo Medical Center
-
Orlando, Florida, Verenigde Staten, 32803
- AdventHealth Orlando
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Emory University
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Northwestern University
-
-
Michigan
-
Lansing, Michigan, Verenigde Staten, 48910
- McLaren Greater Lansing
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64111
- Saint Luke's Hospital of Kansas City
-
Springfield, Missouri, Verenigde Staten, 65804
- Mercy Hospital Springfield
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68105
- Nebraska Medical Center
-
-
New Jersey
-
Camden, New Jersey, Verenigde Staten, 08103
- Virtua Health
-
-
New York
-
Buffalo, New York, Verenigde Staten, 14203
- SUNY, The University of Buffalo/Gates Vascular
-
New York, New York, Verenigde Staten, 10075
- Northwell Health
-
Rochester, New York, Verenigde Staten, 14642
- University of Rochester Medical Center
-
Stony Brook, New York, Verenigde Staten, 11794
- Stony Brook University Hospital
-
The Bronx, New York, Verenigde Staten, 10467
- Montefiore Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45219
- University of Cincinnati Medical Center
-
Cleveland, Ohio, Verenigde Staten, 44195
- The Cleveland Clinic Foundation
-
Columbus, Ohio, Verenigde Staten, 43210
- Ohio State University - Wexner Medical Center
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Verenigde Staten, 18015
- St. Luke's University Hospital
-
Erie, Pennsylvania, Verenigde Staten, 16507
- UPMC Hamot
-
Erie, Pennsylvania, Verenigde Staten, 16505
- AHN Saint Vincent Hospital
-
Harrisburg, Pennsylvania, Verenigde Staten, 17101
- UPMC Harrisburg
-
Philadelphia, Pennsylvania, Verenigde Staten, 19144
- Thomas Jefferson University
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- The University of Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15213
- UPMC Heart and Vascular Institute
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15212
- Allegheny Health Network Research Institute
-
York, Pennsylvania, Verenigde Staten, 17403
- Wellspan York Hospital
-
-
Tennessee
-
Brentwood, Tennessee, Verenigde Staten, 37027
- HCA Tristar
-
Knoxville, Tennessee, Verenigde Staten, 37920
- UTMC Knoxville
-
Nashville, Tennessee, Verenigde Staten, 37203
- Ascension Saint Thomas Hospital
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75235
- Parkland Hospital
-
Fort Worth, Texas, Verenigde Staten, 76104
- Texas Health Harris Methodist Hospital
-
San Antonio, Texas, Verenigde Staten, 78229
- Methodist Main Hospital
-
Temple, Texas, Verenigde Staten, 76508
- Baylor Scott & White - Temple
-
-
Virginia
-
Falls Church, Virginia, Verenigde Staten, 22042
- Inova Fairfax
-
-
West Virginia
-
Charleston, West Virginia, Verenigde Staten, 25304
- Charleston Area Medical Center
-
Morgantown, West Virginia, Verenigde Staten, 26506
- West Virginia University Ruby Memorial Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, Verenigde Staten, 53215
- Aurora Saint Luke's Medical Center
-
-
-
-
-
Basel, Zwitserland
- Universitaetsspital Basel
-
Bern, Zwitserland
- Universitätsspital Bern
-
Lucerne, Zwitserland
- Luzerner Kantonsspital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Age at enrollment ≥ 18 years
-
Objective evidence of a proximal filling defect in at least one main or lobar pulmonary artery, as confirmed by CTPA, pulmonary angiography, or other imaging modality
-
RV dysfunction, as defined as one or more of the following: RV/LV ratio ≥ 0.9 or RV dilation or hypokinesis
-
At least two additional risk factors, identified by at least one measure in two separate categories noted below:
a. Hemodynamic: i. SBP 90-100mmHg ii. Resting heart rate > 100 bpm b. Biomarker: i. Elevated* cardiac troponin (troponin I or troponin T, conventional or high sensitivity) ii. Elevated* BNP or NT-proBNP iii. Elevated venous lactate ≥2 mmol/L * Elevated, meaning at or above the upper limit of normal, per local standards for the assay used c. Respiratory: i. O2 saturation < 90% on room air ii. Supplemental O2 requirement ≥ 4 L/min iii. Respiratory rate ≥ 20 breaths/min iv. mMRC score > 0
-
Symptom onset within 14 days of confirmed PE diagnosis
-
Willing and able to provide informed consent
Exclusion Criteria:
-
Unable to be anticoagulated with heparin, enoxaparin or other parenteral antithrombin
-
Presentation with hemodynamic instability* that meets the high-risk PE definition in the 2019 ESC Guidelines1, including ANY of the following
- Cardiac arrest OR
- Systolic BP < 90 mmHg or vasopressors required to achieve a BP ≥ 90 mmHg despite adequate filling status, AND end-organ hypoperfusion OR
- Systolic BP < 90 mmHg or systolic BP drop ≥ 40 mmHg, lasting longer than 15 min and not caused by new-onset arrhythmia, hypovolemia, or sepsis * Patients who are stable at time of screening or randomization (i.e., SBP ≥ 90 mmHg and adequate organ perfusion without catecholamine or vasopressor infusion) may be included despite initial presentation including temporary, low-dose catecholamines or vasopressors, or temporary fluid resuscitation.
-
Known sensitivity to radiographic contrast agents that, in the Investigator's opinion, cannot be adequately pre-treated
-
Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the patient is not appropriate for catheter-based intervention (e.g., inability to navigate to target location, clot limited to segmental/subsegmental distribution, predominately chronic clot)
-
End stage medical condition with life expectancy < 3 months, as determined by the Investigator
-
Current participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this study
-
Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis, per 2019 ESC Guidelines1
-
If objective testing was performed*, estimated RV systolic pressure > 70 mmHg on standard of care echocardiography * If clinical suspicion of acute-on-chronic PE, chronic obstruction, or chronic thromboembolism, echocardiographic estimated RVSP must be confirmed ≤70 mmHg to meet eligibility. Pressure assessment not required if Investigator attests to absence of such clinical suspicion
-
Administration of advanced therapies (thrombolytic bolus, thrombolytic drip/infusion, catheter-directed thrombolytic therapy, mechanical thrombectomy, or ECMO) for the index PE event within 30 days prior to enrollment
-
Ventricular arrhythmias refractory to treatment at the time of enrollment
-
Known to have heparin-induced thrombocytopenia (HIT)
-
Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments). This includes a contraindication to use of FlowTriever System per local approved labeling
-
Subject is currently pregnant
-
Subject has previously completed or withdrawn from this study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: FlowTriever
Mechanical thrombectomy for pulmonary embolism using the FlowTriever System. |
Mechanical Thrombectomy for pulmonary embolism |
|
Actieve vergelijker: Anticoagulation
Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. Anticoagulants are a group of medications that decrease your blood's ability to clot. |
Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. Anticoagulants are a group of medications that decrease your blood's ability to clot. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Composite clinical endpoint constructed as a win ratio, a hierarchy of the following, which are assessed post-randomization:
Tijdsspanne: through discharge or 30 days, whichever is sooner / dyspnea at 48 hours
|
|
through discharge or 30 days, whichever is sooner / dyspnea at 48 hours
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Sterfte door alle oorzaken en PE-gerelateerde sterfte
Tijdsspanne: Op 30 en 90 dagen
|
Op 30 en 90 dagen
|
|
|
Heropnames ongeacht de oorzaak en PE-gerelateerde
Tijdsspanne: Op 30 en 90 dagen
|
Op 30 en 90 dagen
|
|
|
6 minuten loopafstand
Tijdsspanne: Bij het bezoek van 1 maand
|
Bij het bezoek van 1 maand
|
|
|
RV/LV-verhouding
Tijdsspanne: Bij het 48-uursbezoek
|
Bij het 48-uursbezoek
|
|
|
Diagnose van post-PE-stoornissen (PPEI)
Tijdsspanne: Tijdens het bezoek van 3 maanden
|
Tijdens het bezoek van 3 maanden
|
|
|
Composite clinical endpoint constructed as a win ratio hierarchy of the following three components, assessed post randomization:
Tijdsspanne: up to 30 days
|
|
up to 30 days
|
|
Clinical deterioration
Tijdsspanne: Through discharge or up to 30 days after randomization, whichever is sooner
|
defined by hemodynamic or respiratory worsening |
Through discharge or up to 30 days after randomization, whichever is sooner
|
|
Bailout therapy
Tijdsspanne: Through discharge or up to 30 days after randomization, whichever is sooner
|
either after a deterioration or after documented failure to progress, |
Through discharge or up to 30 days after randomization, whichever is sooner
|
|
Major Bleeding, defined by the Bleeding Academic Research Consortium (BARC), level 3b, 3c, 5a, or 5b
Tijdsspanne: At 30 and 90 days
|
3b: Overt bleeding plus hemoglobin drop of ≥ 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade, bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid); bleeding requiring intravenous vasoactive agents 3c: Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal), subcategories confirmed by autopsy or imaging or lumbar puncture, intraocular bleed compromising vision. 5a: Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious 5b: Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation |
At 30 and 90 days
|
|
Dyspnea severity by mMRC score
Tijdsspanne: At the 48-hour, 1-month, and 3-month visits
|
0, no breathlessness except on strenuous exercise;
|
At the 48-hour, 1-month, and 3-month visits
|
|
PE-related quality of life, by PEmb-QoL
Tijdsspanne: At the 1- and 3-month visits
|
Pulmonary Embolism Quality of Life: (higher = better) |
At the 1- and 3-month visits
|
|
General health-related quality of life, by EQ-5D-5L
Tijdsspanne: At the 1- and 3-month visits
|
Higher score = worse |
At the 1- and 3-month visits
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Jay Giri, MD, Penn Medicine
- Hoofdonderzoeker: Bernhard Gebauer, MD, Charité University Hospital Berlin
- Hoofdonderzoeker: Felix Mahfoud, MD, Universitaetsspital Basel
- Hoofdonderzoeker: Frances Mae West, MD, Jefferson Health
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 23-001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .